BioSpace News Archive

Innovus Pharmaceuticals, Inc. announced that its marketed product UriVarx® has received approval for an expanded claim to include “helps improve the symptoms of urinary incontinence.” Innovus Pharma currently sells this product in Canada exclusively through its distributor, Acerus Pharmaceuticals Corporation.

Vizient, Inc., the largest member-driven health care performance improvement company in the country, announced the recognition of 23 suppliers and distributors for delivering exceptional service to members.

Activ5 Is Arriving in Style in the UK and Europe’s Online Markets with one of the most forward-thinking names in the logistics and supply chain industry

Milestone Pharmaceuticals announced the appointment of Michael Tomsicek to its Board of Directors.

Former Walgreens executive joins board of directors at rapidly growing leader in medication adherence solutions [04-April-2019] BRENTWOOD, Tenn. , April 4, 2019 /PRNewswire/ -- AdhereHealth ™, a leading healthcare technology company focused on medication adherence, has added healthcare veteran Brad Fluegel to its board of directors. Fluegel, formerly chief healthca

New CEO dedicated to continued excellence and comprehensive care for adult cancer patients with new technology, more clinical research, the latest treatment plans and patient-centered care

AMN Healthcare Services, Inc., healthcare’s leader and innovator in workforce solutions and staffing services, will host a conference call to discuss its first quarter 2019 financial results on Thursday, May 2, 2019 at 5:00 p.m. Eastern Time.

Wearable medical device that helps stroke and spinal cord injury patients stand and relearn to walk now available for south and central Texas patients

Kyowa Hakko Kirin Co., Ltd. announced that the U.S. Food and Drug Administration has accepted for review the resubmitted New Drug Application for istradefylline, an investigational selective adenosine A2A receptor antagonist, for use as adjunctive treatment to levodopa/carbidopa in adult patients with Parkinson’s disease experiencing “OFF” episodes.

Study Met All Primary and Secondary Endpoints